modelCiclopiroxAndZincPyrithi
Extends from Pharmacolibrary.Drugs.ATC.D.D01AE20.
Information
| name: | CiclopiroxAndZincPyrithioneCombination | |
| ATC code: | D01AE20 | route: | topical |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 10 | L |
| clearance: | 0.5 | L/h |
| other parameters in model implementation | ||
This is a topical combination antifungal preparation, containing ciclopirox and zinc pyrithione. Ciclopirox is a broad-spectrum antifungal agent used to treat dermatophytoses, candidiasis, and tinea versicolor; zinc pyrithione is commonly used to treat seborrheic dermatitis and dandruff. This combination has been marketed for use in the treatment of fungal skin infections and seborrheic dermatitis. It is available as a topical formulation and is not intended for systemic use. Ciclopirox combination products are primarily approved for topical use in some countries.
Pharmacokinetics
No published human pharmacokinetic data exist for the topical ciclopirox and zinc pyrithione combination; only estimated pharmacokinetic parameters may be provided. For topical application, systemic absorption of ciclopirox is reported to be less than 5% based on available monotherapy data; zinc pyrithione systemic absorption is negligible.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)